Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

CFRA analyst Wan Nurhayati revised the price target for Novo Nordisk (NYSE:NVO) shares, reducing it to $90 from the previous target of $122. Despite the price target cut, the analyst retained a Hold ...

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the ...

Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...